Mark Spahr

Mark Spahr has over 28 years of experience in the pharmaceutical and biotechnology industries. Mark began their career in 1990 as a Staff Immunologist at Merck, Sharpe and Dohme Pharmaceuticals. In 1992, they joined Pfizer Global Research and Development (PGRD) as a Senior Scientist, where they managed up to five in-vitro colleagues on project teams responsible for experimental protocols, data analysis and quality control. Mark was also a technical and disease expert in Cardiovascular Pharmacology for lipid biochemistry, cellular biology, assay development and a significant scientific contributor to project teams. In 2008, they returned to Cayman Chemical as a Technical Support Representative. From 2010 to 2013, they worked at Esperion Therapeutics as a Senior Scientist, Biology. Mark then moved to Lycera as a Senior Research Scientist before joining IFM Therapeutics in 2020 as a Sr. Research Associate.

Mark Spahr obtained their Masters in Microbioloby and Immunology from the University of Michigan between 1986 and 1990.